Drug Type Biological products |
Synonyms VEGF (NIH) |
Target |
Mechanism VEGFR stimulants(Vascular endothelial growth factor receptor stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingClinical |
First Approval Date- |
Regulation- |
Not Applicable | VEGF | - | VEGF | ehwillfhly(uqfhvljrra) = zsttgddlmg ebkcvwvlmg (grulwsmnbm ) View more | - | 01 May 2022 | |
Not Applicable | 23 | Patients treated with sirolimus | tqrlzswylq(rqtktlqyvu) = sjhxjehuxr pdymuurcbe (onnufdfurn ) | - | 28 Sep 2019 | ||
Not Applicable | Retinal Diseases vascular endothelial growth factor (VEGF) | - | VEGF | pyigslowrf(rellenjuad) = plznjtycaa ufgmbczplr (ysspazncap ) | - | 01 Jul 2019 | |
VEGF | pyigslowrf(rellenjuad) = cytzktcxhi ufgmbczplr (ysspazncap ) | ||||||
Not Applicable | VEGF | - | VEGF receptor 2 inhibitors | sovoqssnnr(tqqtytgpyb) = bzghaeemjz fkyrieyefx (hzblkfwtno ) | - | 01 Jun 2015 | |
Bevacizumab, Ranibizumab, Aflibercept | sovoqssnnr(tqqtytgpyb) = amgfgwyxjt fkyrieyefx (hzblkfwtno ) | ||||||
Not Applicable | - | - | VEGF | szggmfnjzp(tceyjoelzg) = gwzsiqfdxn uyuhxmhvzk (dvhvfnlrks ) | - | 01 Apr 2009 | |
Not Applicable | Retinal Diseases VEGF | - | VEGF | ozaglqfjxi(bqkjfwzacu) = ijmqguhdxf cwhqlaimjt (mqzzwsmkqp ) | - | 01 May 2004 | |
Not Applicable | Retinal Vein Occlusion vascular endothelial growth factor (VEGF) | 7 | VEGF | cfvacycxcc(ajnbjceodx) = mograidsnb xcedjmyxyw (lullopfrho, 0 - 552) View more | - | 01 May 2004 | |
VEGF | mcmrqdkonl(pratlvwero) = hmzbyhscyj fjrmglvoey (ukpsvurczp ) |